BENSON REED L 4

4 · Co-Diagnostics, Inc. · Filed May 21, 2021

Form 4

Period: 2021-05-19

Chief Financial Officer

Transactions

Sale
Common Stock
2021-05-19$8.54/sh−10,920$93,232→ 97,414 total
Sale
Common Stock
2021-05-19$8.52/sh−97,413$830,387→ 1 total
Sale
Common Stock
2021-05-19$8.53/sh−1$9→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-05-19−1→ 13,891 total
Exercise: $1.10Exp: 2029-09-02→ Common Stock (1 underlying)
Exercise/Conversion
Common Stock
2021-05-19$1.10/sh+1$1→ 1 total
Exercise/Conversion
Common Stock
2021-05-19$2.63/sh+10,920$28,720→ 10,921 total
Exercise/Conversion
Common Stock
2021-05-19$2.63/sh+97,413$256,196→ 108,334 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-05-19−97,413→ 0 total
Exercise: $2.63Exp: 2028-09-20→ Common Stock (97,413 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2021-05-19−10,920→ 0 total
Exercise: $2.63Exp: 2028-09-20→ Common Stock (10,920 underlying)

Footnotes (4)

[F1]This transaction was executed in multiple trades at prices ranging from $8.52 USD to $8.55 USD; the price reported above reflects the weighted average sale price.
[F2]This transaction was executed in multiple trades at prices ranging from $8.47 USD to $8.64 USD; the price reported above reflects the weighted average sale price.
[F3]1/3 on day of grant; 1/3 after year 1, 1/3 after year 2 beginning on 21-Sep-2018
[F4]1/3 on day of grant; 1/3 after year 1, 1/3 after year 2 beginning on 03-Sep-2019

Documents

1 file